Maternal phenylketonuria collaborative study (MPKUCS) offspring

Facial anomalies, malformations, and early neurological sequelae

Bobbye Rouse, Colleen Azen, Richard Koch, Reuben Matalon, William Hanley, Felix De La Cruz, Friedrich Trefz, Eva Friedman, Harvey Shifrin

Research output: Contribution to journalArticle

83 Citations (Scopus)

Abstract

Maternal phenylketonuria (PKU) in untreated women has resulted in offspring with microcephaly, mental retardation, congenital heart disease (CHD), and intrauterine growth retardation. The Maternal Phenylketonuria Collaborative Study (MPKUCS) was designed to determine the effect of dietary control of blood phenylalanine (Phe) during pregnancy in preventing damage to the fetus associated with untreated Maternal PKU. A cohort of offspring from MPKUS pregnancies was ascertained and examined to evaluate malformations, including CHD, craniofacial abnormalities, microcephaly, intrauterine and postnatal growth retardation, other major and minor defects, and early abnormal neurological signs. For analysis, the women were grouped according to their mean Phe levels in μmol/liter, ±360, 361-600, 601-900, or >900, during critical gestational weeks of 0-8 (N = 203) and 8-12 (N = 190), and average for Phe exposure throughout pregnancy (N = 183). Frequencies of congenital abnormalities increased with increasing maternal Phe levels. Significant relationships included average Phe 0-8 weeks and CHD (P = 0.001); average Phe 8-12 weeks and brain, fetal, and postnatal growth retardation (P < 0.0005 for all), wide nasal bridge (P < 0.0005), and anteverted nares (P = 0.001); and average Phe exposure during the entire pregnancy and neurological signs (P < 0.0005). Although 14% of infants had CHD, none of the CHD occurred at 120-360 μmol/liter and only one (3%) at 361600 μmol/liter. At levels of 120-360 μmol/liter, there were three infants (6%) with microcephaly, two (4%) with post-natal growth, and none with intrauterine growth retardation, in contrast to 85%, 51%, and 26%, respectively, with Phe above 900 μmol/liter. These data support the concept that women with PKU should begin a low-phenylalanine diet to achieve Phe levels of <360 μmol/liter prior to conception and should maintain this throughout pregnancy.

Original languageEnglish (US)
Pages (from-to)89-95
Number of pages7
JournalAmerican Journal of Medical Genetics
Volume69
Issue number1
DOIs
StatePublished - Mar 3 1997
Externally publishedYes

Fingerprint

Maternal Phenylketonuria
Phenylalanine
Fetal Growth Retardation
Heart Diseases
Microcephaly
Pregnancy
Craniofacial Abnormalities
Phenylketonurias
Nose
Intellectual Disability

Keywords

  • congenital heart disease
  • facial dysmorphology
  • maternal phenylketonuria
  • microcephaly
  • MPKU

ASJC Scopus subject areas

  • Genetics(clinical)

Cite this

Maternal phenylketonuria collaborative study (MPKUCS) offspring : Facial anomalies, malformations, and early neurological sequelae. / Rouse, Bobbye; Azen, Colleen; Koch, Richard; Matalon, Reuben; Hanley, William; De La Cruz, Felix; Trefz, Friedrich; Friedman, Eva; Shifrin, Harvey.

In: American Journal of Medical Genetics, Vol. 69, No. 1, 03.03.1997, p. 89-95.

Research output: Contribution to journalArticle

Rouse, Bobbye ; Azen, Colleen ; Koch, Richard ; Matalon, Reuben ; Hanley, William ; De La Cruz, Felix ; Trefz, Friedrich ; Friedman, Eva ; Shifrin, Harvey. / Maternal phenylketonuria collaborative study (MPKUCS) offspring : Facial anomalies, malformations, and early neurological sequelae. In: American Journal of Medical Genetics. 1997 ; Vol. 69, No. 1. pp. 89-95.
@article{d4f9a306220c44a58563b528bd7872f0,
title = "Maternal phenylketonuria collaborative study (MPKUCS) offspring: Facial anomalies, malformations, and early neurological sequelae",
abstract = "Maternal phenylketonuria (PKU) in untreated women has resulted in offspring with microcephaly, mental retardation, congenital heart disease (CHD), and intrauterine growth retardation. The Maternal Phenylketonuria Collaborative Study (MPKUCS) was designed to determine the effect of dietary control of blood phenylalanine (Phe) during pregnancy in preventing damage to the fetus associated with untreated Maternal PKU. A cohort of offspring from MPKUS pregnancies was ascertained and examined to evaluate malformations, including CHD, craniofacial abnormalities, microcephaly, intrauterine and postnatal growth retardation, other major and minor defects, and early abnormal neurological signs. For analysis, the women were grouped according to their mean Phe levels in μmol/liter, ±360, 361-600, 601-900, or >900, during critical gestational weeks of 0-8 (N = 203) and 8-12 (N = 190), and average for Phe exposure throughout pregnancy (N = 183). Frequencies of congenital abnormalities increased with increasing maternal Phe levels. Significant relationships included average Phe 0-8 weeks and CHD (P = 0.001); average Phe 8-12 weeks and brain, fetal, and postnatal growth retardation (P < 0.0005 for all), wide nasal bridge (P < 0.0005), and anteverted nares (P = 0.001); and average Phe exposure during the entire pregnancy and neurological signs (P < 0.0005). Although 14{\%} of infants had CHD, none of the CHD occurred at 120-360 μmol/liter and only one (3{\%}) at 361600 μmol/liter. At levels of 120-360 μmol/liter, there were three infants (6{\%}) with microcephaly, two (4{\%}) with post-natal growth, and none with intrauterine growth retardation, in contrast to 85{\%}, 51{\%}, and 26{\%}, respectively, with Phe above 900 μmol/liter. These data support the concept that women with PKU should begin a low-phenylalanine diet to achieve Phe levels of <360 μmol/liter prior to conception and should maintain this throughout pregnancy.",
keywords = "congenital heart disease, facial dysmorphology, maternal phenylketonuria, microcephaly, MPKU",
author = "Bobbye Rouse and Colleen Azen and Richard Koch and Reuben Matalon and William Hanley and {De La Cruz}, Felix and Friedrich Trefz and Eva Friedman and Harvey Shifrin",
year = "1997",
month = "3",
day = "3",
doi = "10.1002/(SICI)1096-8628(19970303)69:1<89::AID-AJMG17>3.0.CO;2-K",
language = "English (US)",
volume = "69",
pages = "89--95",
journal = "American Journal of Medical Genetics, Part A",
issn = "1552-4825",
publisher = "Wiley-Liss Inc.",
number = "1",

}

TY - JOUR

T1 - Maternal phenylketonuria collaborative study (MPKUCS) offspring

T2 - Facial anomalies, malformations, and early neurological sequelae

AU - Rouse, Bobbye

AU - Azen, Colleen

AU - Koch, Richard

AU - Matalon, Reuben

AU - Hanley, William

AU - De La Cruz, Felix

AU - Trefz, Friedrich

AU - Friedman, Eva

AU - Shifrin, Harvey

PY - 1997/3/3

Y1 - 1997/3/3

N2 - Maternal phenylketonuria (PKU) in untreated women has resulted in offspring with microcephaly, mental retardation, congenital heart disease (CHD), and intrauterine growth retardation. The Maternal Phenylketonuria Collaborative Study (MPKUCS) was designed to determine the effect of dietary control of blood phenylalanine (Phe) during pregnancy in preventing damage to the fetus associated with untreated Maternal PKU. A cohort of offspring from MPKUS pregnancies was ascertained and examined to evaluate malformations, including CHD, craniofacial abnormalities, microcephaly, intrauterine and postnatal growth retardation, other major and minor defects, and early abnormal neurological signs. For analysis, the women were grouped according to their mean Phe levels in μmol/liter, ±360, 361-600, 601-900, or >900, during critical gestational weeks of 0-8 (N = 203) and 8-12 (N = 190), and average for Phe exposure throughout pregnancy (N = 183). Frequencies of congenital abnormalities increased with increasing maternal Phe levels. Significant relationships included average Phe 0-8 weeks and CHD (P = 0.001); average Phe 8-12 weeks and brain, fetal, and postnatal growth retardation (P < 0.0005 for all), wide nasal bridge (P < 0.0005), and anteverted nares (P = 0.001); and average Phe exposure during the entire pregnancy and neurological signs (P < 0.0005). Although 14% of infants had CHD, none of the CHD occurred at 120-360 μmol/liter and only one (3%) at 361600 μmol/liter. At levels of 120-360 μmol/liter, there were three infants (6%) with microcephaly, two (4%) with post-natal growth, and none with intrauterine growth retardation, in contrast to 85%, 51%, and 26%, respectively, with Phe above 900 μmol/liter. These data support the concept that women with PKU should begin a low-phenylalanine diet to achieve Phe levels of <360 μmol/liter prior to conception and should maintain this throughout pregnancy.

AB - Maternal phenylketonuria (PKU) in untreated women has resulted in offspring with microcephaly, mental retardation, congenital heart disease (CHD), and intrauterine growth retardation. The Maternal Phenylketonuria Collaborative Study (MPKUCS) was designed to determine the effect of dietary control of blood phenylalanine (Phe) during pregnancy in preventing damage to the fetus associated with untreated Maternal PKU. A cohort of offspring from MPKUS pregnancies was ascertained and examined to evaluate malformations, including CHD, craniofacial abnormalities, microcephaly, intrauterine and postnatal growth retardation, other major and minor defects, and early abnormal neurological signs. For analysis, the women were grouped according to their mean Phe levels in μmol/liter, ±360, 361-600, 601-900, or >900, during critical gestational weeks of 0-8 (N = 203) and 8-12 (N = 190), and average for Phe exposure throughout pregnancy (N = 183). Frequencies of congenital abnormalities increased with increasing maternal Phe levels. Significant relationships included average Phe 0-8 weeks and CHD (P = 0.001); average Phe 8-12 weeks and brain, fetal, and postnatal growth retardation (P < 0.0005 for all), wide nasal bridge (P < 0.0005), and anteverted nares (P = 0.001); and average Phe exposure during the entire pregnancy and neurological signs (P < 0.0005). Although 14% of infants had CHD, none of the CHD occurred at 120-360 μmol/liter and only one (3%) at 361600 μmol/liter. At levels of 120-360 μmol/liter, there were three infants (6%) with microcephaly, two (4%) with post-natal growth, and none with intrauterine growth retardation, in contrast to 85%, 51%, and 26%, respectively, with Phe above 900 μmol/liter. These data support the concept that women with PKU should begin a low-phenylalanine diet to achieve Phe levels of <360 μmol/liter prior to conception and should maintain this throughout pregnancy.

KW - congenital heart disease

KW - facial dysmorphology

KW - maternal phenylketonuria

KW - microcephaly

KW - MPKU

UR - http://www.scopus.com/inward/record.url?scp=0031046763&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031046763&partnerID=8YFLogxK

U2 - 10.1002/(SICI)1096-8628(19970303)69:1<89::AID-AJMG17>3.0.CO;2-K

DO - 10.1002/(SICI)1096-8628(19970303)69:1<89::AID-AJMG17>3.0.CO;2-K

M3 - Article

VL - 69

SP - 89

EP - 95

JO - American Journal of Medical Genetics, Part A

JF - American Journal of Medical Genetics, Part A

SN - 1552-4825

IS - 1

ER -